Mechanistic PK/PD modeling to address early-stage biotherapeutic dosing feasibility questions

Published in mAbs

Next-Generation Conjugates Summit
Feb 21, 2023 - Feb 23, 2023
Molecular Glue Drug Development Summit
Jan 24, 2023 - Jan 26, 2023
22nd Annual PepTalk
Jan 16, 2023 - Jan 20, 2023

Predicting on-target, off-tumor toxicity of Solitomab, an EpCAM/CD3 BiTE

Applied BioMath Assess™ can be used to optimize the design of CD3 bispecific T-cell engagers by evaluating the risk of on-target, off-tumor toxicities and to make an early prediction about therapeutic index and projections of effective and tolerable doses for T-cell engagers in solid tumors. In this case study, we will demonstrate the ability to predict the on-target, off-tumor toxicity observed for solitomab, a drug that failed to meet its end points due to dose limiting toxicity.

Applied BioMath Assess™ Optimizing Avidity of Bispecific Drugs

Bispecific drugs have great potential to improve tissue selectivity through avid binding interactions, but introduce non-trivial drug design parameters that must be considered as part of target selection and lead identification.

This case study demonstrates how to use Applied BioMath Assess™ to identify the level of avidity required for a drug to have a favorable efficacy and therapeutic index. It also illustrates how drug design decisions can benefit from modeling and simulation due to non-trivial impacts on drug behavior.

View the video demo


Subscribe to Our Software